Overview
Follistatin-344 is classified as a myostatin inhibitor peptide. Muscle hypertrophy, strength.
Blocks myostatin (the body's muscle growth limiter) and activin, allowing enhanced muscle development and regeneration beyond normal physiological limits.
Also known as: FS-344
Category
Myostatin Inhibitor
Half-Life
6h
Route
SubQ
FDA Status
Not Approved
How Does Follistatin-344 Work?
Blocks myostatin (the body's muscle growth limiter) and activin, allowing enhanced muscle development and regeneration beyond normal physiological limits.
At the molecular level, Follistatin-344 operates through pathways characteristic of the Myostatin Inhibitor class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Follistatin gene therapy increases muscle mass and strength
Rodino-Klapac et al. (Mol. Ther.): AAV-delivered follistatin 344 increases muscle mass and fiber diameter across multiple animal species without adverse reproductive or endocrine effects.
Evidence: preclinical[2]Follistatin as myostatin antagonist therapeutic potential
Kalista et al.: Review of follistatin's role as primary endogenous myostatin antagonist and its therapeutic potential for muscular dystrophies and sarcopenia.
Evidence: preclinical[3]Follistatin gene transfer for Becker muscular dystrophy (Phase I)
Mendell et al. (Mol. Ther.): Phase I clinical trial of AAV1-follistatin gene transfer in Becker muscular dystrophy patients shows improved 6-minute walk test with no adverse effects.
Evidence: moderate[4]Follistatin in adipocyte differentiation and energy metabolism
Research demonstrating follistatin's broader metabolic role in adipocyte browning, energy expenditure, and metabolic health beyond muscle hypertrophy.
Evidence: preclinicalSafety Profile
Research-only. Potent effects potential for unregulated growth. Limited human safety data. Phase I gene therapy trials show safety.
| Side Effect | Incidence | Severity |
|---|---|---|
| Limited human safety data | Investigational only | mild |
| Injection site reaction | ~5% of users | mild |
| Theoretical cancer promotion | Mechanism-based concern | rare |
Sourcing Follistatin-344 for Research
If you're looking to source Follistatin-344 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Follistatin-344 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.